Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

PubWeight™: 12.21‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 20472172)

Published in Lancet on May 15, 2010

Authors

Kennedy R Lees1, Erich Bluhmki, Rüdiger von Kummer, Thomas G Brott, Danilo Toni, James C Grotta, Gregory W Albers, Markku Kaste, John R Marler, Scott A Hamilton, Barbara C Tilley, Stephen M Davis, Geoffrey A Donnan, Werner Hacke, ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Kathryn Allen, Jochen Mau, Dieter Meier, Gregory del Zoppo, D A De Silva, K S Butcher, M W Parsons, P A Barber, C Levi, C Bladin, G Byrnes

Author Affiliations

1: Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK. k.r.lees@clinmed.gla.ac.uk

Associated clinical trials:

Sedation vs. Intubation for Endovascular Stroke TreAtment (SIESTA) | NCT02126085

Prehospital Management of Stroke Patients by Emergency Medical Services | NCT02191514

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) (TALISMAN) | NCT02180204

Articles citing this

(truncated to the top 100)

Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet (2012) 10.30

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet (2014) 10.26

Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ (2010) 4.74

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet (2012) 4.66

Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol (2014) 3.61

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.55

Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2014) 1.76

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke (2012) 1.76

High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol (2013) 1.75

Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. AJNR Am J Neuroradiol (2013) 1.71

Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial. Int J Stroke (2012) 1.55

Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53

MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial. Trials (2014) 1.51

The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab (2011) 1.47

Multiparametric MRI and CT models of infarct core and favorable penumbral imaging patterns in acute ischemic stroke. Stroke (2012) 1.43

Optimization modeling to maximize population access to comprehensive stroke centers. Neurology (2015) 1.42

Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab (2013) 1.41

Three simple rules to ensure reasonably credible subgroup analyses. BMJ (2015) 1.40

Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol (2011) 1.39

Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci U S A (2011) 1.32

A concerted appeal for international cooperation in preclinical stroke research. Stroke (2013) 1.32

Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. Int J Stroke (2013) 1.25

Bringing rigour to translational medicine. Nat Rev Neurol (2013) 1.16

Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review. Expert Rev Cardiovasc Ther (2011) 1.14

The effect of out of hours presentation with acute stroke on processes of care and outcomes: analysis of data from the Stroke Improvement National Audit Programme (SINAP). PLoS One (2014) 1.11

Disparities in evaluation at certified primary stroke centers: reasons for geographic and racial differences in stroke. Stroke (2013) 1.11

Endovascular therapy for ischemic stroke. J Clin Neurol (2015) 1.09

Refining the mismatch concept in acute stroke: lessons learned from PET and MRI. J Cereb Blood Flow Metab (2012) 1.07

Stroke penumbra defined by an MRI-based oxygen challenge technique: 2. Validation based on the consequences of reperfusion. J Cereb Blood Flow Metab (2011) 1.04

The history and future of telestroke. Nat Rev Neurol (2013) 1.03

Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med (2010) 1.02

Impact of intensive care unit admission during morning bedside rounds and mortality: a multi-center retrospective cohort study. Crit Care (2012) 1.02

Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program. Circ Cardiovasc Qual Outcomes (2012) 1.00

Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional Surgery. J Am Coll Radiol (2013) 0.99

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99

Review of stroke thrombolytics. J Stroke (2013) 0.98

Point-of-care testing in the overcrowded emergency department--can it make a difference? Crit Care (2014) 0.97

Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab (2014) 0.97

Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J Vasc Interv Neurol (2012) 0.97

A time series evaluation of the FAST National Stroke Awareness Campaign in England. PLoS One (2014) 0.97

Evaluation of interval times from onset to reperfusion in patients undergoing endovascular therapy in the Interventional Management of Stroke III trial. Circulation (2014) 0.96

Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci (2014) 0.96

Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A (2014) 0.95

Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. Ann Neurol (2013) 0.95

A review of decision support, risk communication and patient information tools for thrombolytic treatment in acute stroke: lessons for tool developers. BMC Health Serv Res (2013) 0.95

MR imaging of oxygen extraction and neurovascular coupling. Stroke (2013) 0.95

Door-to-puncture: a practical metric for capturing and enhancing system processes associated with endovascular stroke care, preliminary results from the rapid reperfusion registry. J Am Heart Assoc (2014) 0.95

Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC. PLoS One (2011) 0.95

Alteplase for ischaemic stroke--much sooner is much better. Lancet (2010) 0.94

Immune interventions in stroke. Nat Rev Neurol (2015) 0.94

Field Assessment Stroke Triage for Emergency Destination: A Simple and Accurate Prehospital Scale to Detect Large Vessel Occlusion Strokes. Stroke (2016) 0.94

Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside. Transl Stroke Res (2010) 0.94

Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies. Stroke (2015) 0.93

Disparities in accessibility of certified primary stroke centers. Stroke (2014) 0.93

Translation of the 'time is brain' concept into clinical practice: focus on prehospital stroke management. Int J Stroke (2014) 0.92

Prehospital stroke care: new prospects for treatment and clinical research. Neurology (2013) 0.92

Time to endovascular reperfusion and degree of disability in acute stroke. Ann Neurol (2015) 0.92

Intra-hospital delays in stroke patients treated with rt-PA: impact of preadmission notification. J Neurol (2012) 0.91

Development of a computerised decision aid for thrombolysis in acute stroke care. BMC Med Inform Decis Mak (2015) 0.91

Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ (2014) 0.91

Site of hospital readmission and mortality: a population-based retrospective cohort study. CMAJ Open (2014) 0.91

ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost (2012) 0.90

Assessment of acute stroke cerebral CT examinations by anaesthesiologists. Acta Anaesthesiol Scand (2015) 0.90

Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci U S A (2012) 0.90

Blood-brain barrier permeability derangements in posterior circulation ischemic stroke: frequency and relation to hemorrhagic transformation. J Neurol Sci (2011) 0.89

Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. Neurology (2014) 0.89

Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates? Neurol Clin Pract (2015) 0.89

Wake-up stroke: clinical characteristics, imaging findings, and treatment option - an update. Front Neurol (2014) 0.88

Sustained impact of UK FAST-test public education on response to stroke: a population-based time-series study. Int J Stroke (2015) 0.88

Patterns, predictors, variations, and temporal trends in emergency medical service hospital prenotification for acute ischemic stroke. J Am Heart Assoc (2012) 0.88

Fluid-attenuated inversion recovery hyperintensity in acute ischemic stroke may not predict hemorrhagic transformation. Cerebrovasc Dis (2011) 0.88

Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke (2015) 0.88

Magnetic resonance imaging of ischemia viability thresholds and the neurovascular unit. Sensors (Basel) (2013) 0.87

Periprocedural aspects in mechanical recanalization for acute stroke: data from the ENDOSTROKE registry. Neuroradiology (2013) 0.87

Intracranial hemorrhage. Am J Respir Crit Care Med (2011) 0.86

Clinical significance of plasma VEGF value in ischemic stroke - research for biomarkers in ischemic stroke (REBIOS) study. BMC Neurol (2013) 0.86

Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke. Exp Neurol (2014) 0.86

Evaluation of pre-hospital transport time of stroke patients to thrombolytic treatment. Scand J Trauma Resusc Emerg Med (2014) 0.86

Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. Transl Stroke Res (2011) 0.85

Current pathophysiological concepts in cerebral small vessel disease. Front Aging Neurosci (2014) 0.85

Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke. J Cereb Blood Flow Metab (2013) 0.85

In cold blood: intraarteral cold infusions for selective brain cooling in stroke. J Cereb Blood Flow Metab (2014) 0.84

Efficacy and safety of endovascular treatment versus intravenous thrombolysis for acute ischemic stroke: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.84

Stroke warning campaigns: delivering better patient outcomes? A systematic review. Patient Relat Outcome Meas (2015) 0.84

The potential roles of 18F-FDG-PET in management of acute stroke patients. Biomed Res Int (2013) 0.84

Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost (2014) 0.84

THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial. Int J Stroke (2014) 0.84

Inflammatory Disequilibrium in Stroke. Circ Res (2016) 0.83

Rate of Contrast Extravasation on Computed Tomographic Angiography Predicts Hematoma Expansion and Mortality in Primary Intracerebral Hemorrhage. Stroke (2015) 0.83

Stroke damage detection using classification trees on electrical bioimpedance cerebral spectroscopy measurements. Sensors (Basel) (2013) 0.83

The 2012 Feinberg Lecture: treatment swift and treatment sure. Stroke (2012) 0.83

Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial. J Neurointerv Surg (2013) 0.83

Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice. J Cereb Blood Flow Metab (2014) 0.83

Safety and clinical outcome of thrombolysis in ischaemic stroke using a perfusion CT mismatch between 3 and 6 hours. PLoS One (2011) 0.83

Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke. Ther Hypothermia Temp Manag (2013) 0.82

The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost (2012) 0.82

Eligibility assessment for intravenous thrombolytic therapy in acute ischemic stroke patients; evaluating barriers for implementation. Iran Red Crescent Med J (2014) 0.82

Process improvement to enhance existing stroke team activity toward more timely thrombolytic treatment. J Clin Neurol (2014) 0.82

Prehospital utility of rapid stroke evaluation using in-ambulance telemedicine: a pilot feasibility study. Stroke (2014) 0.82

Articles by these authors

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92

Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke (2007) 12.77

Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 12.06

Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke (2010) 10.66

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Stroke. Lancet (2008) 9.51

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 9.41

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02

Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19

Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 7.89

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

1,026 experimental treatments in acute stroke. Ann Neurol (2006) 7.23

Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96

National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94

Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke (2009) 6.62

Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01

MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91

Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med (2014) 5.79

NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32

Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32

Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation (2007) 5.28

Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke (2005) 5.18

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet (2007) 4.99

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet (2012) 4.66

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39

Pooling of animal experimental data reveals influence of study design and publication bias. Stroke (2004) 4.37

Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust (2003) 4.24

Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14

Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 4.13

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98

Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91

Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke (2008) 3.87

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86

NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51

Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke (2010) 3.43

Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke (2009) 3.39

Unravelling Mycosphaerella: do you believe in genera? Persoonia (2009) 3.31

Good laboratory practice: preventing introduction of bias at the bench. Stroke (2008) 3.27

Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21

Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab (2005) 3.20

A three-item scale for the early prediction of stroke recovery. Lancet (2001) 3.15

Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol (2012) 3.11

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11

Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07

Prognostic value of brain diffusion-weighted imaging after cardiac arrest. Ann Neurol (2009) 3.05

Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging (2010) 3.03

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03

A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol (2007) 2.99

Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke (2007) 2.95

Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain (2007) 2.94

Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology (2012) 2.91

Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87

National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82

Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol (2002) 2.79

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time. Ann Neurol (2013) 2.77

Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet (2010) 2.74

High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. Stroke (2000) 2.72

European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke (2014) 2.71

Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke (2012) 2.64

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64